Celldex director granted 26,000 stock options
Celldex Therapeutics, Inc. director Harry Jr Penner reported receiving a grant of non-qualified stock options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Celldex Therapeutics, Inc. director Harry Jr Penner reported receiving a grant of non-qualified stock options. The award covers 26,000 options to buy Celldex common stock at an exercise price of $34.09 per share, expiring on June 25, 2036. The options, issued at no cost to the director, were granted under the company’s 2021 Omnibus Equity Incentive Plan and leave him holding 26,000 derivative securities following the transaction. This is a compensation-related grant rather than an open-market share purchase or sale.
Insider Trade Summary
Grant/Award: 26,000 shares
Grant/Award
1 txn
Insider
PENNER HARRY JR
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Option (right to buy) | 26,000 | $0.00 | $0.00 |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 26,000 contracts (Direct)
Footnotes (1)
- F1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
Key Figures
Options granted: 26,000 options
Exercise price: $34.09 per share
Expiration date: June 25, 2036
+2 more
5 metrics
Options granted
26,000 options
Non-qualified stock options granted to director
Exercise price
$34.09 per share
Strike price of granted options
Expiration date
June 25, 2036
Option expiration
Cost of grant
$0.00 per option
Options granted at no upfront cost
Derivative holdings after grant
26,000 options
Total derivative securities following transaction
Key Terms
Non-Qualified Stock Option, 2021 Omnibus Equity Incentive Plan, grant/award acquisition, exercise price, +1 more
5 terms
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
2021 Omnibus Equity Incentive Plan financial
"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."
grant/award acquisition financial
"transaction_action: grant/award acquisition"
exercise price financial
"conversion_or_exercise_price: 34.0900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
derivative securities financial
"total_shares_following_transaction: 26000.0000"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Celldex (CLDX) director Harry Jr Penner report in this Form 4?
Harry Jr Penner reported receiving a grant of 26,000 non-qualified stock options in Celldex. These options give him the right to buy common shares at a fixed price, reflecting equity-based compensation rather than an open-market transaction.
How many Celldex (CLDX) options were granted to the director and at what price?
The director was granted 26,000 non-qualified stock options with an exercise price of $34.09 per share. This strike price is the cost per share he must pay to convert each option into Celldex common stock in the future.
When do Harry Jr Penner’s Celldex (CLDX) stock options expire?
The 26,000 non-qualified stock options granted to Harry Jr Penner expire on June 25, 2036. After this expiration date, any unexercised options will lapse and no longer give him the right to purchase Celldex common shares.
Is the Celldex (CLDX) Form 4 a stock purchase or sale by the director?
The Form 4 reflects a grant of stock options, not a market purchase or sale. It is classified as a grant or award acquisition, meaning the director received options as compensation rather than buying or selling existing Celldex shares in the open market.
Under which plan were the Celldex (CLDX) options granted to the director?
The 26,000 stock options were granted under Celldex’s 2021 Omnibus Equity Incentive Plan. This plan authorizes the company to issue equity-based awards, such as options, to directors and employees as part of their overall compensation package.
How many derivative securities does the Celldex (CLDX) director hold after this grant?
Following the grant, the director holds 26,000 derivative securities in the form of non-qualified stock options. This entire position comes from the new award, and reflects his potential future right to acquire Celldex common stock at the set exercise price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates